Statistics from Altmetric.com
It was with great interest that I read the e-letter by Drs Kataria and Ravindran1 directed to a recent article of mine in the new Annals of the Rheumatic Diseases section ‘Thinking the unthinkable’.2 Their comments are much appreciated, especially since they re-emphasise the upcoming disruption in chronic diseases, but also outline the complexity that many tools will not yet be approved by regulatory authorities for use in daily routine care. Digital biomarkers will be important for the prediction of clinical outcomes, and they rightly point out that patterns arising from genome-wide association studies could be helpful in providing insights into disease pathology. They also allude to the important item of data protection, which has become even more important in Europe with the introduction of the New European General Data Protection Regulation,3 which strongly enforces patients’ rights. Finally, they rightly emphasise the role of the human being in artificial intelligence algorithms to validate the findings of these novel approaches. In the future, we will have to leave the sometimes comfortable cocoon to step into the digital world—of course aiming for a better and more rapid patient care.
Handling editor Josef S Smolen
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.
Correction notice This article has been corrected since it published Online First. Reference 1 has been corrected.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.